Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Quantitative Imaging and Radiomics in Multiple Myeloma: opportunity or hype?

Version 1 : Received: 20 November 2020 / Approved: 23 November 2020 / Online: 23 November 2020 (09:17:03 CET)

How to cite: Tagliafico, A.S.; Dominietto, A.; Belgioia, L.; Campi, C.; Schenone, D.; Piana, M. Quantitative Imaging and Radiomics in Multiple Myeloma: opportunity or hype?. Preprints 2020, 2020110569 (doi: 10.20944/preprints202011.0569.v1). Tagliafico, A.S.; Dominietto, A.; Belgioia, L.; Campi, C.; Schenone, D.; Piana, M. Quantitative Imaging and Radiomics in Multiple Myeloma: opportunity or hype?. Preprints 2020, 2020110569 (doi: 10.20944/preprints202011.0569.v1).

Abstract

Multiple Myeloma (MM) is the second most common type of hematological disease and, although it is rare among patients under 40 years of age, its incidence rises in elderly subject. MM manifestations are usually known with the abbreviation CRAB (hyperCalcemia, Renal failure, Anaemia, and lytic Bone lesions). In particular, the extent of the bone disease is negatively related to a decreased patients’ quality of life and, in general, bone disease in MM increases both morbidity and mortality. The detection of lytic bone lesions on imaging, especially CT and MRI, is becoming crucial from the clinical viewpoint to separate asymptomatic from symptomatic MM patients and the detection of focal lytic lesion in these imaging data is becoming relevant even when no clinical symptoms are present. Therefore, radiology is pivotal in the staging and accurate management of patients with MM even in early phases of the disease. In this review we describe the opportunities offered by quantitative imaging and radiomics in multiple myeloma. At present time there is still high variability in the choice between various imaging methods to study MM patients and high variability in image interpretation with suboptimal agreement among readers even in tertiary centres. Therefore, the potential of medical imaging for patients affected by MM is still to be completely unveiled. In the next years, new insights to study MM with medical imaging will derive from artificial intelligence (AI) and radiomics usage in different bone lesions and from the wide implementations of quantitative methods to report CT and MRI. Eventually, medical imaging data can be integrated with the patient's outcomes with the purpose to find radiological biomarkers for predicting the disease prognostic flow and its therapeutic response.

Subject Areas

multiple myeloma; computed tomography; artificial intelligence; radiomics; prognosis; imaging; diagnosis

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.